NDA 206426 · Biocryst
Rapivab
Peramivir · Intravenous
NovelLast checked: Nov 20, 2026Latest source record: Jun 13, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Dec 19, 2014
Approved uses
3
Original approval plus efficacy supplements
Registered trials
18
10 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 28, 2021 Supplement 7 · Efficacy · priority review LetterLabel
- Sep 20, 2017 Supplement 4 · Efficacy · priority review LabelLetterPediatric Medical Review
- Dec 19, 2014 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
1 products under this application
- RAPIVAB · PERAMIVIR 200MG/20ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Peramivir" as an intervention, any sponsor and status, largest first.
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05648448 · 3,000 participants (planned) · Start Feb 22, 2023 · Primary completion Jan 1, 2027
Drug: Oseltamivir; Favipiravir and 8 more · For: Influenza; Influenza, Human
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 4 sites in all
- Efficacy and Safety of Inhaled Peramivir Solution for the Treatment of Adults With Uncomplicated InfluenzaPivotal-lookingNot yet recruiting
Capital Medical UniversityAcademic, hospital or other
NCT07791251 · 600 participants (planned) · Start Oct 28, 2026 · Primary completion Apr 6, 2028
Drug: Peramivir Inhalation Solution; Placebo for Peramivir Inhalation Solution · For: Influenza Infection
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to InfluenzaPivotal-lookingTerminated
BioCryst PharmaceuticalsIndustry
NCT00958776 · 405 participants · Start Nov 2009 · Primary completion Nov 2012
Drug: Peramivir+SOC; Placebo+SOC · For: Cough; Sore Throat; Nasal Congestion and 3 more
Sites: La Mesa, California; Long Beach, California; Modesto, California · 196 sites in all
- A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute InfluenzaPivotal-lookingCompleted
BioCryst PharmaceuticalsIndustry
NCT00705406 · 405 participants · Start Jul 2008 · Primary completion Apr 2009
Drug: Peramivir; Placebo · For: Acute, Uncomplicated Human Influenza
Sites: Birmingham, Alabama; Phoenix, Arizona; Jonesboro, Arkansas · 123 sites in all
- Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe InfluenzaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03684044 · 363 participants · Start Jan 8, 2019 · Primary completion Mar 16, 2020
Drug: Baloxavir Marboxil · For: Influenza
Sites: Torrance, California; Denver, Colorado; Decatur, Georgia · 170 sites in all
- Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.Pivotal-lookingCompleted
BioCryst PharmaceuticalsIndustry
NCT00419263 · 344 participants · Start Jan 2007 · Primary completion Sep 2007
Drug: Peramivir 150 mg; Peramivir 300 mg and 1 more · For: Influenza
Sites: Birmingham, Alabama; Jonesboro, Arkansas; Anaheim, California · 69 sites in all
- Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected InfluenzaPivotal-lookingCompleted
BioCryst PharmaceuticalsIndustry
NCT00957996 · 234 participants · Start Oct 2009 · Primary completion Oct 2010
Drug: Peramivir; Peramivir · For: Seasonal Influenza; Cough; Sore Throat and 4 more
Sites: Dothan, Alabama; Mobile, Alabama; Jonesboro, Arkansas · 110 sites in all
- ED Influenza Therapeutic Pilot Study: Oseltamivir vs. PeramivirPivotal-lookingCompleted
Johns Hopkins UniversityAcademic, hospital or other
NCT02609399 · 180 participants · Start Nov 1, 2015 · Primary completion May 26, 2017
Drug: Oseltamivir; Peramivir · For: Influenza
Sites: Phoenix, Arizona; Baltimore, Maryland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials.
Gao Y, Guyatt G, Uyeki TM, et al. · Lancet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis.
Gao Y, Zhao Y, Liu M, et al. · JAMA Intern Med 2025 · Network Meta-Analysis, Systematic Review
- Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
Kumar D, Ison MG, Mira JP, et al. · Lancet Infect Dis 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy of Pharmacotherapy for Seasonal Influenza in Young and Middle-aged Adults: A Systematic Review and Network Meta-analysis.
Hanaki N, Sakaniwa R, Moromizato T, et al. · Intern Med 2024 · Systematic Review, Network Meta-Analysis
- Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis.
Liu JW, Lin SH, Wang LC, et al. · JAMA Netw Open 2021 · Systematic Review, Network Meta-Analysis
- Virological response to peramivir treatment in adults hospitalised for influenza-associated lower respiratory tract infections.
Lee N, Chan PK, Tam WW, et al. · Int J Antimicrob Agents 2016 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Biocryst
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.